Pfizer terminates Phase III obesity drug development program
Based on all currently available information and an ongoing review of the Phase III program by an independent data monitoring committee, Pfizer believes that the CP-945,598 compound has
Tolerance Bio has signed an agreement securing an exclusive licence from Tanabe Pharma for TLB-33, a clinical-stage anti-IL-33 monoclonal antibody, in a deal that includes potential development and sales milestone payments of up to around $560m.